<!DOCTYPE html>
<html lang="en">
<head>
<meta charset="utf-8">
<meta name="viewport" content="width=device-width,initial-scale=1">
<title>Oxaliplatin decreases Oxaliplatin accumulation in resistant HCT116 cells — pCite</title>
<link rel="stylesheet" href="../css/style.css">
</head>
<body>
<header>
  <h1><a href="../index.html">pCite</a></h1>
  <nav><a href="../index.html">Search</a><a href="../corpus.html">Corpus</a></nav>
</header>

<p class="section-label">CLAIM</p>
<hr class="section-rule">
<div class="triple">
  <strong>Oxaliplatin</strong>
  <span class="pred">&mdash;decreases&rarr;</span>
  <strong>Oxaliplatin accumulation in resistant HCT116 cells</strong>
</div>
<div class="entity-id">CHEBI:31941 &nbsp;&middot;&nbsp; UNKNOWN:oxaliplatin_accumulation_resistant</div>

<p class="section-label">VALIDATION</p>
<hr class="section-rule">
<div class="val-bar" style="--pct:5%;--color:#f0a030"></div>
<div class="stat-row">
  <span>Class: Curated (0.5)</span>
  <span>Replicated: 1 paper</span>
  <span>Score: 80.00<span class="score-tip"><span class="tip-icon">&nbsp;&#9432;</span><span class="tip-text">Score = &Sigma; incoming citation weights. Each citation is weighted by the validation class of the source claim (Physical 10.0 &middot; Curated 0.5 &middot; AI 0.01) multiplied by the citation type (Replicates 1.5 &middot; Supports 1.0 &middot; Contradicts 0.8). A score of 364 means this claim received strong physical-tier citation support.</span></span></span>
</div>

<p class="section-label">EVIDENCE CHAIN &middot; 1 source</p>
<hr class="section-rule">
<div class="evidence-row"><span class="evidence-dot" style="background:#f0a030" title="Curated"></span><span>Curated</span><a href="https://doi.org/10.1039/c9mt00141g">10.1039/c9mt00141g</a></div>


<p class="section-label">CITATIONS RECEIVED &middot; 9 total</p>
<hr class="section-rule">
<div class="cite-bar"><span style="width:70px;text-align:right">Replicates</span><span class="cite-bar-fill" style="width:0px"></span><span>0</span></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Supports</span><span class="cite-bar-fill" style="width:100px"></span><span>5</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">Dual-column LC-HRMS (RP+HILIC) method — distinguishes → xenobiotics and human estrogens</span><a href="../claim/c2ca0154c16e2f41.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">Dual-column LC-HRMS xenobiotic LOD in solvent — is_biomarker_for → xenobiotics and human estrogens in solvent</span><a href="../claim/20416d509767a19a.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">Dual-column LC-HRMS xenobiotic LOD in urine — is_biomarker_for → xenobiotics and human estrogens in urine</span><a href="../claim/82e6ce105f974283.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">Dual-column LC-HRMS xenobiotic LOD in plasma — is_biomarker_for → xenobiotics and human estrogens in plasma</span><a href="../claim/bd2a18dc63a847af.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">sub-Saharan Africa urine exposome profile — distinguishes → high chemical exposure scenario</span><a href="../claim/33cf05b6e5d00cc2.html">view &rarr;</a></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Contradicts</span><span class="cite-bar-fill" style="width:60px"></span><span>3</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">Dual-column LC-HRMS endogenous metabolite LOD — is_biomarker_for → endogenous metabolites in solvent</span><a href="../claim/cdb50081d34e1bc6.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">European urine exposome profile — distinguishes → low chemical exposure scenario</span><a href="../claim/522e6d83a0fd3922.html">view &rarr;</a></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">Chemical exposome — causes → disrupted metabolic pathways</span><a href="../claim/5710a5b7701976cb.html">view &rarr;</a></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Extends</span><span class="cite-bar-fill" style="width:0px"></span><span>0</span></div>
<div class="cite-bar"><span style="width:70px;text-align:right">Applies</span><span class="cite-bar-fill" style="width:20px"></span><span>1</span></div>
<div class="cite-claim"><span class="evidence-dot" style="background:#2ca02c"></span><span class="cite-claim-triple">Dual-column LC-HRMS (RP+HILIC) method — distinguishes → endogenous metabolites</span><a href="../claim/a9040c05215d3992.html">view &rarr;</a></div>


<p class="section-label">IDENTIFIERS</p>
<hr class="section-rule">
<table class="id-table">
<tr><td>Claim ID</td><td><code>abb738e4c47d1eba</code></td></tr>
<tr><td>Subject URI</td><td><a href="https://identifiers.org/CHEBI:31941">CHEBI:31941</a></td></tr>
<tr><td>Object URI</td><td><a href="https://identifiers.org/UNKNOWN:oxaliplatin_accumulation_resistant">UNKNOWN:oxaliplatin_accumulation_resistant</a></td></tr>
</table>
<footer>pCite — validation-weighted scientific claims</footer>
</body>
</html>
